View : 300 Download: 0
Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology
- Title
- Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology
- Authors
- Jung, Eun Hee; Hong, Junshik; Kim, Sung-Yong; Park, Young; Yuh, Young Jin; Mun, Yeung-Chul; Lee, Won-Sik; Park, Sung-Kyu; Bang, Soo Mee
- Ewha Authors
- 문영철
- SCOPUS Author ID
- 문영철
- Issue Date
- 2022
- Journal Title
- CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
- ISSN
- 2152-2650
2152-2669
- Citation
- CLINICAL LYMPHOMA MYELOMA & LEUKEMIA vol. 22, no. 10, pp. E931 - E937
- Keywords
- Anemia; Red Blood Cell Transfusion; Myelofibrosis; Ruxolitinib; Transfusion
- Publisher
- CIG MEDIA GROUP, LP
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- We evaluated the treatment outcome of ruxolitinib, especially focused on RBC TF and anemia in 123 MF patients in a real-world setting. Approximately one-third showed long-term and severe transfusion dependence, respectively. In addition, the presence of MF-related anemia was a risk factor for predicting RBC TF dependency throughout the ruxolitinib treatment. Given these data, patients with = 2 units of RBC TF over eight weeks at the time of ruxolitinib initiation need more supportive care with awareness of the risk of anemia in actual practice. Introduction/Background: Ruxolitinib is an established treatment for myelofibrosis (MF) that has demonstrated clinical benefit by reducing spleen size and debilitating MF-related symptoms. However, despite the efficacy of ruxolitinib, anemia remains a major adverse event that causes dose modification or discontinuation in real-world practice. Additionally, dependence on red blood cell (RBC) transfusion (TF) is common during treatment; therefore, we explored the outcome of ruxolitinib therapy with a primary focus on RBC TF. Patients/Methods: We retrospectively reviewed the medical records of 123 MF patients treated with ruxolitinib between January 2012 and April 2020 at eight academic centers in Korea. Results: At ruxolitinib initiation, 38 patients (30.9%) underwent >= 2 units of RBC TF over 8 weeks. The most common reason for permanent discontinuation was intolerant anemia (10/63, 15.9%). The most common reasons for temporary interruption were nonhematologic toxicity (26/55, 21.1%), anemia (23/55, 18.7%) and thrombocytopenia (13/55, 10.6%). Among the 123 patients in the study, 57 (46.3%), 42 (34.1%), and 40 patients (32.5%) who were receiving or stopped ruxolitinib therapy had a status of RBC TF dependence, long-term RBC TF dependence, or severe RBC TF dependence, respectively. The presence of = 2 units of RBC transfusion over 8 weeks at ruxolitinib initiation was an independent risk factor for persistent RBC TF dependence. Conclusion: The requirement for RBC TF is commonly encountered during treatment of MF with ruxolitinib, particularly among those with pre-existing = 2 units of RBC TF over 8 weeks. For those patients, overcoming the barrier of maintenance TF is demanding.
- DOI
- 10.1016/j.clml.2022.06.008
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML